Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
LPI (LP Information)' newest research report, the “13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Industry Forecast” looks at past sales and reviews total world 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) sales in 2022, providing a comprehensive analysis by region and market sector of projected 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) sales for 2023 through 2029. With 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) industry.
This Insight Report provides a comprehensive analysis of the global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13).
The global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) players cover Pfizer, Minhai Bio, Kexing Bio, Cansino Bio and Lanzhou Biological Preparations Institute, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market?
What factors are driving 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market opportunities vary by end market size?
How does 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Industry Forecast” looks at past sales and reviews total world 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) sales in 2022, providing a comprehensive analysis by region and market sector of projected 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) sales for 2023 through 2029. With 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) industry.
This Insight Report provides a comprehensive analysis of the global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13).
The global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) players cover Pfizer, Minhai Bio, Kexing Bio, Cansino Bio and Lanzhou Biological Preparations Institute, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Serotype 6B
- 7F Serotype
- Serotype 9V
- 14 Serotype
- Serotype 18C
- Serotype 19A
- 19F Serotype
- 23F Serotype
- 24F Serotype
- Other
- Infants from 6 Weeks to 15 Months Old
- Children Aged 15 Months to 5 Years
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Minhai Bio
- Kexing Bio
- Cansino Bio
- Lanzhou Biological Preparations Institute
What is the 10-year outlook for the global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market?
What factors are driving 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market opportunities vary by end market size?
How does 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Country/Region, 2018, 2022 & 2029
2.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Segment by Type
2.2.1 Serotype 6B
2.2.2 7F Serotype
2.2.3 Serotype 9V
2.2.4 14 Serotype
2.2.5 Serotype 18C
2.2.6 Serotype 19A
2.2.7 19F Serotype
2.2.8 23F Serotype
2.2.9 24F Serotype
2.2.10 Other
2.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type
2.3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2018-2023)
2.3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Market Share by Type (2018-2023)
2.3.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sale Price by Type (2018-2023)
2.4 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Segment by Application
2.4.1 Infants from 6 Weeks to 15 Months Old
2.4.2 Children Aged 15 Months to 5 Years
2.5 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application
2.5.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sale Market Share by Application (2018-2023)
2.5.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Market Share by Application (2018-2023)
2.5.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sale Price by Application (2018-2023)
3 GLOBAL 13-VALENT PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (PCV13) BY COMPANY
3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Breakdown Data by Company
3.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Sales by Company (2018-2023)
3.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Company (2018-2023)
3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Revenue by Company (2018-2023)
3.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Company (2018-2023)
3.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Company (2018-2023)
3.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sale Price by Company
3.4 Key Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Location Distribution
3.4.2 Players 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR 13-VALENT PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (PCV13) BY GEOGRAPHIC REGION
4.1 World Historic 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Geographic Region (2018-2023)
4.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Sales by Geographic Region (2018-2023)
4.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Country/Region (2018-2023)
4.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Sales by Country/Region (2018-2023)
4.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Revenue by Country/Region (2018-2023)
4.3 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Growth
4.4 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Growth
4.5 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Growth
4.6 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Growth
5 AMERICAS
5.1 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country
5.1.1 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2018-2023)
5.1.2 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2018-2023)
5.2 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type
5.3 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region
6.1.1 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2018-2023)
6.1.2 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2018-2023)
6.2 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type
6.3 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Country
7.1.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2018-2023)
7.1.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2018-2023)
7.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type
7.3 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Country
8.1.1 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2018-2023)
8.1.2 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2018-2023)
8.2 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type
8.3 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
10.3 Manufacturing Process Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
10.4 Industry Chain Structure of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Distributors
11.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Customer
12 WORLD FORECAST REVIEW FOR 13-VALENT PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (PCV13) BY GEOGRAPHIC REGION
12.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size Forecast by Region
12.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Forecast by Region (2024-2029)
12.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Forecast by Type
12.7 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
13.1.3 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Minhai Bio
13.2.1 Minhai Bio Company Information
13.2.2 Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
13.2.3 Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Minhai Bio Main Business Overview
13.2.5 Minhai Bio Latest Developments
13.3 Kexing Bio
13.3.1 Kexing Bio Company Information
13.3.2 Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
13.3.3 Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Kexing Bio Main Business Overview
13.3.5 Kexing Bio Latest Developments
13.4 Cansino Bio
13.4.1 Cansino Bio Company Information
13.4.2 Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
13.4.3 Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Cansino Bio Main Business Overview
13.4.5 Cansino Bio Latest Developments
13.5 Lanzhou Biological Preparations Institute
13.5.1 Lanzhou Biological Preparations Institute Company Information
13.5.2 Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
13.5.3 Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Lanzhou Biological Preparations Institute Main Business Overview
13.5.5 Lanzhou Biological Preparations Institute Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Country/Region, 2018, 2022 & 2029
2.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Segment by Type
2.2.1 Serotype 6B
2.2.2 7F Serotype
2.2.3 Serotype 9V
2.2.4 14 Serotype
2.2.5 Serotype 18C
2.2.6 Serotype 19A
2.2.7 19F Serotype
2.2.8 23F Serotype
2.2.9 24F Serotype
2.2.10 Other
2.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type
2.3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2018-2023)
2.3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Market Share by Type (2018-2023)
2.3.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sale Price by Type (2018-2023)
2.4 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Segment by Application
2.4.1 Infants from 6 Weeks to 15 Months Old
2.4.2 Children Aged 15 Months to 5 Years
2.5 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application
2.5.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sale Market Share by Application (2018-2023)
2.5.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue and Market Share by Application (2018-2023)
2.5.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sale Price by Application (2018-2023)
3 GLOBAL 13-VALENT PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (PCV13) BY COMPANY
3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Breakdown Data by Company
3.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Sales by Company (2018-2023)
3.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Company (2018-2023)
3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Revenue by Company (2018-2023)
3.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Company (2018-2023)
3.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Company (2018-2023)
3.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sale Price by Company
3.4 Key Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Location Distribution
3.4.2 Players 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR 13-VALENT PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (PCV13) BY GEOGRAPHIC REGION
4.1 World Historic 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Geographic Region (2018-2023)
4.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Sales by Geographic Region (2018-2023)
4.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Country/Region (2018-2023)
4.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Sales by Country/Region (2018-2023)
4.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Revenue by Country/Region (2018-2023)
4.3 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Growth
4.4 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Growth
4.5 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Growth
4.6 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Growth
5 AMERICAS
5.1 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country
5.1.1 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2018-2023)
5.1.2 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2018-2023)
5.2 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type
5.3 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region
6.1.1 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2018-2023)
6.1.2 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2018-2023)
6.2 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type
6.3 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Country
7.1.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2018-2023)
7.1.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2018-2023)
7.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type
7.3 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Country
8.1.1 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2018-2023)
8.1.2 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2018-2023)
8.2 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type
8.3 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
10.3 Manufacturing Process Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
10.4 Industry Chain Structure of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Distributors
11.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Customer
12 WORLD FORECAST REVIEW FOR 13-VALENT PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (PCV13) BY GEOGRAPHIC REGION
12.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size Forecast by Region
12.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Forecast by Region (2024-2029)
12.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Forecast by Type
12.7 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
13.1.3 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Minhai Bio
13.2.1 Minhai Bio Company Information
13.2.2 Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
13.2.3 Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Minhai Bio Main Business Overview
13.2.5 Minhai Bio Latest Developments
13.3 Kexing Bio
13.3.1 Kexing Bio Company Information
13.3.2 Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
13.3.3 Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Kexing Bio Main Business Overview
13.3.5 Kexing Bio Latest Developments
13.4 Cansino Bio
13.4.1 Cansino Bio Company Information
13.4.2 Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
13.4.3 Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Cansino Bio Main Business Overview
13.4.5 Cansino Bio Latest Developments
13.5 Lanzhou Biological Preparations Institute
13.5.1 Lanzhou Biological Preparations Institute Company Information
13.5.2 Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
13.5.3 Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Lanzhou Biological Preparations Institute Main Business Overview
13.5.5 Lanzhou Biological Preparations Institute Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Serotype 6B
Table 4. Major Players of 7F Serotype
Table 5. Major Players of Serotype 9V
Table 6. Major Players of 14 Serotype
Table 7. Major Players of Serotype 18C
Table 8. Major Players of Serotype 19A
Table 9. Major Players of 19F Serotype
Table 10. Major Players of 23F Serotype
Table 11. Major Players of 24F Serotype
Table 12. Major Players of Other
Table 13. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2018-2023) & (K Units)
Table 14. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2018-2023)
Table 15. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2018-2023) & ($ million)
Table 16. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Type (2018-2023)
Table 17. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sale Price by Type (2018-2023) & (US$/Unit)
Table 18. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2018-2023) & (K Units)
Table 19. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2018-2023)
Table 20. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2018-2023)
Table 21. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Application (2018-2023)
Table 22. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sale Price by Application (2018-2023) & (US$/Unit)
Table 23. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Company (2018-2023) & (K Units)
Table 24. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Company (2018-2023)
Table 25. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Company (2018-2023) ($ Millions)
Table 26. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Company (2018-2023)
Table 27. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sale Price by Company (2018-2023) & (US$/Unit)
Table 28. Key Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Producing Area Distribution and Sales Area
Table 29. Players 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Products Offered
Table 30. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 31. New Products and Potential Entrants
Table 32. Mergers & Acquisitions, Expansion
Table 33. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Geographic Region (2018-2023) & (K Units)
Table 34. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share Geographic Region (2018-2023)
Table 35. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Geographic Region (2018-2023) & ($ millions)
Table 36. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Geographic Region (2018-2023)
Table 37. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country/Region (2018-2023) & (K Units)
Table 38. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country/Region (2018-2023)
Table 39. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country/Region (2018-2023) & ($ millions)
Table 40. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country/Region (2018-2023)
Table 41. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2018-2023) & (K Units)
Table 42. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country (2018-2023)
Table 43. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2018-2023) & ($ Millions)
Table 44. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country (2018-2023)
Table 45. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2018-2023) & (K Units)
Table 46. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2018-2023) & (K Units)
Table 47. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2018-2023) & (K Units)
Table 48. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region (2018-2023)
Table 49. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2018-2023) & ($ Millions)
Table 50. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Region (2018-2023)
Table 51. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2018-2023) & (K Units)
Table 52. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2018-2023) & (K Units)
Table 53. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2018-2023) & (K Units)
Table 54. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country (2018-2023)
Table 55. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2018-2023) & ($ Millions)
Table 56. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country (2018-2023)
Table 57. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2018-2023) & (K Units)
Table 58. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2018-2023) & (K Units)
Table 59. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2018-2023) & (K Units)
Table 60. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country (2018-2023)
Table 61. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2018-2023) & ($ Millions)
Table 62. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country (2018-2023)
Table 63. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2018-2023) & (K Units)
Table 64. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2018-2023) & (K Units)
Table 65. Key Market Drivers & Growth Opportunities of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
Table 66. Key Market Challenges & Risks of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
Table 67. Key Industry Trends of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
Table 68. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Distributors List
Table 71. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Customer List
Table 72. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Forecast by Region (2024-2029) & (K Units)
Table 73. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Forecast by Region (2024-2029) & ($ millions)
Table 74. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Forecast by Region (2024-2029) & (K Units)
Table 77. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Forecast by Region (2024-2029) & ($ millions)
Table 78. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Forecast by Country (2024-2029) & (K Units)
Table 79. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 80. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Forecast by Country (2024-2029) & (K Units)
Table 81. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 82. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Forecast by Type (2024-2029) & (K Units)
Table 83. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 84. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Forecast by Application (2024-2029) & (K Units)
Table 85. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 86. Pfizer Basic Information, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturing Base, Sales Area and Its Competitors
Table 87. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
Table 88. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 89. Pfizer Main Business
Table 90. Pfizer Latest Developments
Table 91. Minhai Bio Basic Information, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturing Base, Sales Area and Its Competitors
Table 92. Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
Table 93. Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 94. Minhai Bio Main Business
Table 95. Minhai Bio Latest Developments
Table 96. Kexing Bio Basic Information, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturing Base, Sales Area and Its Competitors
Table 97. Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
Table 98. Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 99. Kexing Bio Main Business
Table 100. Kexing Bio Latest Developments
Table 101. Cansino Bio Basic Information, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturing Base, Sales Area and Its Competitors
Table 102. Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
Table 103. Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 104. Cansino Bio Main Business
Table 105. Cansino Bio Latest Developments
Table 106. Lanzhou Biological Preparations Institute Basic Information, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturing Base, Sales Area and Its Competitors
Table 107. Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
Table 108. Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 109. Lanzhou Biological Preparations Institute Main Business
Table 110. Lanzhou Biological Preparations Institute Latest Developments
Table 1. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Serotype 6B
Table 4. Major Players of 7F Serotype
Table 5. Major Players of Serotype 9V
Table 6. Major Players of 14 Serotype
Table 7. Major Players of Serotype 18C
Table 8. Major Players of Serotype 19A
Table 9. Major Players of 19F Serotype
Table 10. Major Players of 23F Serotype
Table 11. Major Players of 24F Serotype
Table 12. Major Players of Other
Table 13. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2018-2023) & (K Units)
Table 14. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2018-2023)
Table 15. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Type (2018-2023) & ($ million)
Table 16. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Type (2018-2023)
Table 17. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sale Price by Type (2018-2023) & (US$/Unit)
Table 18. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2018-2023) & (K Units)
Table 19. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2018-2023)
Table 20. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Application (2018-2023)
Table 21. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Application (2018-2023)
Table 22. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sale Price by Application (2018-2023) & (US$/Unit)
Table 23. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Company (2018-2023) & (K Units)
Table 24. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Company (2018-2023)
Table 25. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Company (2018-2023) ($ Millions)
Table 26. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Company (2018-2023)
Table 27. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sale Price by Company (2018-2023) & (US$/Unit)
Table 28. Key Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Producing Area Distribution and Sales Area
Table 29. Players 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Products Offered
Table 30. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 31. New Products and Potential Entrants
Table 32. Mergers & Acquisitions, Expansion
Table 33. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Geographic Region (2018-2023) & (K Units)
Table 34. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share Geographic Region (2018-2023)
Table 35. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Geographic Region (2018-2023) & ($ millions)
Table 36. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Geographic Region (2018-2023)
Table 37. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country/Region (2018-2023) & (K Units)
Table 38. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country/Region (2018-2023)
Table 39. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country/Region (2018-2023) & ($ millions)
Table 40. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country/Region (2018-2023)
Table 41. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2018-2023) & (K Units)
Table 42. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country (2018-2023)
Table 43. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2018-2023) & ($ Millions)
Table 44. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country (2018-2023)
Table 45. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2018-2023) & (K Units)
Table 46. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2018-2023) & (K Units)
Table 47. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2018-2023) & (K Units)
Table 48. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region (2018-2023)
Table 49. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2018-2023) & ($ Millions)
Table 50. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Region (2018-2023)
Table 51. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2018-2023) & (K Units)
Table 52. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2018-2023) & (K Units)
Table 53. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2018-2023) & (K Units)
Table 54. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country (2018-2023)
Table 55. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2018-2023) & ($ Millions)
Table 56. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country (2018-2023)
Table 57. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2018-2023) & (K Units)
Table 58. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2018-2023) & (K Units)
Table 59. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2018-2023) & (K Units)
Table 60. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country (2018-2023)
Table 61. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2018-2023) & ($ Millions)
Table 62. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country (2018-2023)
Table 63. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Type (2018-2023) & (K Units)
Table 64. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Application (2018-2023) & (K Units)
Table 65. Key Market Drivers & Growth Opportunities of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
Table 66. Key Market Challenges & Risks of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
Table 67. Key Industry Trends of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
Table 68. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Distributors List
Table 71. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Customer List
Table 72. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Forecast by Region (2024-2029) & (K Units)
Table 73. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Forecast by Region (2024-2029) & ($ millions)
Table 74. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Forecast by Region (2024-2029) & (K Units)
Table 77. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Forecast by Region (2024-2029) & ($ millions)
Table 78. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Forecast by Country (2024-2029) & (K Units)
Table 79. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 80. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Forecast by Country (2024-2029) & (K Units)
Table 81. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 82. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Forecast by Type (2024-2029) & (K Units)
Table 83. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 84. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Forecast by Application (2024-2029) & (K Units)
Table 85. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 86. Pfizer Basic Information, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturing Base, Sales Area and Its Competitors
Table 87. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
Table 88. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 89. Pfizer Main Business
Table 90. Pfizer Latest Developments
Table 91. Minhai Bio Basic Information, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturing Base, Sales Area and Its Competitors
Table 92. Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
Table 93. Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 94. Minhai Bio Main Business
Table 95. Minhai Bio Latest Developments
Table 96. Kexing Bio Basic Information, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturing Base, Sales Area and Its Competitors
Table 97. Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
Table 98. Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 99. Kexing Bio Main Business
Table 100. Kexing Bio Latest Developments
Table 101. Cansino Bio Basic Information, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturing Base, Sales Area and Its Competitors
Table 102. Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
Table 103. Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 104. Cansino Bio Main Business
Table 105. Cansino Bio Latest Developments
Table 106. Lanzhou Biological Preparations Institute Basic Information, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturing Base, Sales Area and Its Competitors
Table 107. Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolios and Specifications
Table 108. Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 109. Lanzhou Biological Preparations Institute Main Business
Table 110. Lanzhou Biological Preparations Institute Latest Developments
LIST OF FIGURES
Figure 1. Picture of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
Figure 2. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Serotype 6B
Figure 10. Product Picture of 7F Serotype
Figure 11. Product Picture of Serotype 9V
Figure 12. Product Picture of 14 Serotype
Figure 13. Product Picture of Serotype 18C
Figure 14. Product Picture of Serotype 19A
Figure 15. Product Picture of 19F Serotype
Figure 16. Product Picture of 23F Serotype
Figure 17. Product Picture of 24F Serotype
Figure 18. Product Picture of Other
Figure 19. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type in 2022
Figure 20. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Type (2018-2023)
Figure 21. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Consumed in Infants from 6 Weeks to 15 Months Old
Figure 22. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market: Infants from 6 Weeks to 15 Months Old (2018-2023) & (K Units)
Figure 23. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Consumed in Children Aged 15 Months to 5 Years
Figure 24. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market: Children Aged 15 Months to 5 Years (2018-2023) & (K Units)
Figure 25. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2022)
Figure 26. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Application in 2022
Figure 27. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market by Company in 2022 (K Units)
Figure 28. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Company in 2022
Figure 29. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market by Company in 2022 ($ Million)
Figure 30. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Company in 2022
Figure 31. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Geographic Region (2018-2023)
Figure 32. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Geographic Region in 2022
Figure 33. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales 2018-2023 (K Units)
Figure 34. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue 2018-2023 ($ Millions)
Figure 35. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales 2018-2023 (K Units)
Figure 36. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue 2018-2023 ($ Millions)
Figure 37. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales 2018-2023 (K Units)
Figure 38. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue 2018-2023 ($ Millions)
Figure 39. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales 2018-2023 (K Units)
Figure 40. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue 2018-2023 ($ Millions)
Figure 41. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country in 2022
Figure 42. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country in 2022
Figure 43. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2018-2023)
Figure 44. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2018-2023)
Figure 45. United States 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 46. Canada 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 47. Mexico 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 48. Brazil 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 49. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region in 2022
Figure 50. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Regions in 2022
Figure 51. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2018-2023)
Figure 52. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2018-2023)
Figure 53. China 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 54. Japan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 55. South Korea 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 56. Southeast Asia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 57. India 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 58. Australia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 59. China Taiwan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 60. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country in 2022
Figure 61. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country in 2022
Figure 62. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2018-2023)
Figure 63. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2018-2023)
Figure 64. Germany 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 65. France 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 66. UK 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 67. Italy 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 68. Russia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 69. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country in 2022
Figure 70. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country in 2022
Figure 71. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2018-2023)
Figure 72. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2018-2023)
Figure 73. Egypt 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 74. South Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 75. Israel 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 76. Turkey 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 77. GCC Country 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 78. Manufacturing Cost Structure Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) in 2022
Figure 79. Manufacturing Process Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
Figure 80. Industry Chain Structure of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
Figure 81. Channels of Distribution
Figure 82. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Forecast by Region (2024-2029)
Figure 83. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share Forecast by Region (2024-2029)
Figure 84. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share Forecast by Type (2024-2029)
Figure 85. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share Forecast by Type (2024-2029)
Figure 86. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share Forecast by Application (2024-2029)
Figure 87. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
Figure 2. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Serotype 6B
Figure 10. Product Picture of 7F Serotype
Figure 11. Product Picture of Serotype 9V
Figure 12. Product Picture of 14 Serotype
Figure 13. Product Picture of Serotype 18C
Figure 14. Product Picture of Serotype 19A
Figure 15. Product Picture of 19F Serotype
Figure 16. Product Picture of 23F Serotype
Figure 17. Product Picture of 24F Serotype
Figure 18. Product Picture of Other
Figure 19. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type in 2022
Figure 20. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Type (2018-2023)
Figure 21. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Consumed in Infants from 6 Weeks to 15 Months Old
Figure 22. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market: Infants from 6 Weeks to 15 Months Old (2018-2023) & (K Units)
Figure 23. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Consumed in Children Aged 15 Months to 5 Years
Figure 24. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market: Children Aged 15 Months to 5 Years (2018-2023) & (K Units)
Figure 25. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2022)
Figure 26. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Application in 2022
Figure 27. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market by Company in 2022 (K Units)
Figure 28. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Company in 2022
Figure 29. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market by Company in 2022 ($ Million)
Figure 30. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Company in 2022
Figure 31. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Geographic Region (2018-2023)
Figure 32. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Geographic Region in 2022
Figure 33. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales 2018-2023 (K Units)
Figure 34. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue 2018-2023 ($ Millions)
Figure 35. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales 2018-2023 (K Units)
Figure 36. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue 2018-2023 ($ Millions)
Figure 37. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales 2018-2023 (K Units)
Figure 38. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue 2018-2023 ($ Millions)
Figure 39. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales 2018-2023 (K Units)
Figure 40. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue 2018-2023 ($ Millions)
Figure 41. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country in 2022
Figure 42. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country in 2022
Figure 43. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2018-2023)
Figure 44. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2018-2023)
Figure 45. United States 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 46. Canada 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 47. Mexico 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 48. Brazil 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 49. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region in 2022
Figure 50. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Regions in 2022
Figure 51. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2018-2023)
Figure 52. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2018-2023)
Figure 53. China 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 54. Japan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 55. South Korea 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 56. Southeast Asia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 57. India 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 58. Australia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 59. China Taiwan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 60. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country in 2022
Figure 61. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country in 2022
Figure 62. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2018-2023)
Figure 63. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2018-2023)
Figure 64. Germany 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 65. France 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 66. UK 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 67. Italy 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 68. Russia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 69. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country in 2022
Figure 70. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country in 2022
Figure 71. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2018-2023)
Figure 72. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2018-2023)
Figure 73. Egypt 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 74. South Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 75. Israel 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 76. Turkey 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 77. GCC Country 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth 2018-2023 ($ Millions)
Figure 78. Manufacturing Cost Structure Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) in 2022
Figure 79. Manufacturing Process Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
Figure 80. Industry Chain Structure of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
Figure 81. Channels of Distribution
Figure 82. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Forecast by Region (2024-2029)
Figure 83. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share Forecast by Region (2024-2029)
Figure 84. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share Forecast by Type (2024-2029)
Figure 85. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share Forecast by Type (2024-2029)
Figure 86. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share Forecast by Application (2024-2029)
Figure 87. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share Forecast by Application (2024-2029)
